Any feedback?
Literature summary for 4.1.3.1 extracted from
- Advances in mycobacterial isocitrate lyase targeting and inhibitors (2012), Curr. Med. Chem., 19, 6126-6137.
Application
| Application | Comment | Organism |
|---|---|---|
| drug development | the enzyme is a target for anti-mycobacterial drug development | Mycobacterium tuberculosis |
Inhibitors
| Inhibitors | Comment | Organism | Structure |
|---|---|---|---|
| 1-cyclopropyl-7-[3,5-dimethyl-4-(3-nitropropanoyl)piperazin-1-yl]-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | a fluoroquinolone derivative and structural analogue of succinate | Mycobacterium tuberculosis |  |
Organism
| Organism | UniProt | Comment | Textmining |
|---|---|---|---|
| Mycobacterium tuberculosis | - |
- |
- |
IC50 Value
| IC50 Value | IC50 Value Maximum | Comment | Organism | Inhibitor | Structure |
|---|---|---|---|---|---|
| 0.0001 | - |
pH and temperature not specified in the publication | Mycobacterium tuberculosis | 1-cyclopropyl-7-[3,5-dimethyl-4-(3-nitropropanoyl)piperazin-1-yl]-6-fluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylic acid | |
General Information
| General Information | Comment | Organism |
|---|---|---|
| physiological function | isocitrate lyase plays a key role for survival of Mycobacterium tuberculosis in the latent form during a chronic stage of infection. The enzyme is important during steady stage growth when it converts isocitrate to succinate and glyoxylate | Mycobacterium tuberculosis |
Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.
Release 2023.1 (January 2023)
Legal
Curated at
Member of
